First key steps in pipeline rebuild and strong commercial progress in H1 2022
Cost of sales related to Jyseleca net sales in the first six months of 2022 amounted to 5.5 million.
- Cost of sales related to Jyseleca net sales in the first six months of 2022 amounted to 5.5 million.
- Collaboration revenues amounted to 238.6 million for the first six months of 2022, compared to 253.2 million for the first six months of 2021.
- Depreciation and impairment amounted to 32.6 million for the first six months of 2022 (8.1 million for the same period last year).
- The preliminary accounting of the acquisitions of CellPoint and AboundBio are included in our H1 2022 condensed consolidated financial statements.